{
    "nctId": "NCT04252300",
    "briefTitle": "Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants",
    "officialTitle": "Open Label, Fixed Sequences, One-way Cross-over Study to Determine the Effects of Multiple Doses BAY1817080 (150 mg) on the Pharmacokinetics of a 5 mg Dose Rosuvastatin in Healthy Participants",
    "overallStatus": "COMPLETED",
    "conditions": "Drug Interactions",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Maximum plasma concentration of rosuvastatin without concomitant administration of BAY1817080 (Cmax)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant is healthy as determined by the investigator\n* White or Black race\n* Body mass index (BMI) \u2265 18.0 and \u2264 30.0 kg/m\u00b2 at screening\n* Body weight of at least 50 kg at screening\n\nExclusion Criteria:\n\n* Known or suspected allergy or hypersensitivity to BAY1817080, rosuvastatin or any of their excipients\n* Asian race\n* Contraindications to rosuvastatin\n* Any use of systemic or topically active medication or herbal remedies, prescription or non-prescription, within 1 week prior to the first study intervention administration or during the study until follow-up (occasional use of ibuprofen is permissible)\n* History of or positive COVID-19 test or contact with COVID-19 positive subject in past 4 weeks",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}